Friedreich's Ataxia News and Research

RSS
Friedreich's ataxia is an inherited disease that causes progressive damage to the nervous system resulting in symptoms ranging from gait disturbance and speech problems to heart disease. A well-known celebrity afflicted with Friedreich's ataxia is former major leaguer and noted historian Clinton Stewart.
Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Santhera, Ipsen partner to develop and commercialize fipamezole outside North America and Japan

Muscular Dystrophy Association awards $14.1M in new grants

Muscular Dystrophy Association awards $14.1M in new grants

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

MDA awards $14.1 million in new grants to advance treatments and cures for muscle diseases

Penwest Pharmaceuticals signs merger agreement with Endo Pharmaceuticals

Penwest Pharmaceuticals signs merger agreement with Endo Pharmaceuticals

Endo to acquire Penwest for $5.00 per share

Endo to acquire Penwest for $5.00 per share

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Scientists identify IRP proteins to ensure iron balance for cell survival

Scientists identify IRP proteins to ensure iron balance for cell survival

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen receives three additional grants to develop HDAC inhibitors for neurodegenerative diseases

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen's fiscal 2010 total revenue decreases to $20,971,000

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Repligen's RG2833 granted orphan drug designation for treatment of Friedreich's ataxia

Tufts University's School of Arts and Sciences receives $9.5M grant to create research space

Tufts University's School of Arts and Sciences receives $9.5M grant to create research space

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

Repligen files IND for Phase 1 study of RG2833 selective HDAC-3 inhibitor for Friedreich's ataxia

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

PAREXEL further expands presence in China with offices in Chengdu and Guangzhou

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Aeterna Zentaris posts net loss of $5.9 million for first-quarter 2010

Deficiency of frataxin protein causes Friedreich's ataxia

Deficiency of frataxin protein causes Friedreich's ataxia

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

Penwest Pharmaceuticals reports net income of $3.9 million for first-quarter 2010

Recent business progress at Penwest Pharmaceuticals

Recent business progress at Penwest Pharmaceuticals

Repligen expects total revenue of $21.0M for fiscal year 2010

Repligen expects total revenue of $21.0M for fiscal year 2010

MDA awards over $21M in grants for advancing critical neuromuscular research

MDA awards over $21M in grants for advancing critical neuromuscular research

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy

MDA, FFSHR award $200,000 grant for developing FSH dystrophy therapy